Novartis could face legal action over Zolgensma application
The pharmaceutical company failed to inform the FDA of manipulated data when the gene therapy was under review and could face a legal battle.
List view / Grid view
The pharmaceutical company failed to inform the FDA of manipulated data when the gene therapy was under review and could face a legal battle.
A report has suggested that the drug price reforms in the US will affect AstraZeneca and Novartis negatively, but Novo could benefit.
An integrated Phase I/III trial has enrolled its first patient to test a biosimilar for denosumab to treat postmenopausal osteoporosis.
The US Food and Drug Administration (FDA) has given an investigational sickle cell medicine, crizanlizumab (SEG101), Priority Review.
The global generic drugs market continues to grow. With increasing demand for more accessible medication, pharmaceutical companies are harnessing the benefits offered by generic drugs. Here are the top five generic drugs makers by revenue.
The increasing complexity of formulations and active biological products raises new challenges for pre-filled syringe development. James Mellman, Device Manager at Novartis, speaks to Nikki Withers about the challenges of selecting the right primary packaging for injectable formulations and how he has learnt to expect the unexpected.
GSK and Novartis found to have misled consumers with the packaging and pricing of their osteoarthritis pain treatment.
As today’s scientists continue to identify new biopharmaceutical products with potential to treat a wide array of diseases, formulation remains the determining factor in their success. But what is involved in these increasingly complex formulation processes and how do they impact the packaging and delivery systems?
The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation...
Cablivi and Egaten were the two top novel drugs approved last month, with a focus on parasitic infestation and the rare disorder, aTTP...
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
A report has forecasted that the generic oncology drugs market could register an impressive 6 percent CAGR up to the year 2028...
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise...
The NHS has announced a groundbreaking new treatment, CAR-T, for children with leukaemia...
Researchers found that more than one quarter (26 per cent) of patients taking Aimovig 70mg were migraine free after month 15...